Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Ovation_Pharmaceuticals
gptkb:H._Lundbeck_A/S |
| gptkbp:awards |
various industry recognitions
|
| gptkbp:CEO |
gptkb:Deborah_Dunsire
|
| gptkbp:clinicalTrials |
ongoing
Phase III trials invests heavily Phase I trials Phase II trials |
| gptkbp:collaborations |
international research projects
|
| gptkbp:communityEngagement |
educational programs
support for patients and families mental health awareness campaigns local health initiatives |
| gptkbp:employees |
approximately 5,000
|
| gptkbp:founded |
1915
|
| gptkbp:globalPresence |
over 50 countries
|
| gptkbp:headCoach |
gptkb:Mr._Peter_Sørensen
Dr. Anders Gersel Pedersen Mr. Thomas Møller Ms. Anne Marie Høyer |
| gptkbp:headOfMarketing |
Dr. Lars Jørgensen
|
| gptkbp:headquarters |
Copenhagen,_Denmark
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lundbeck LLC
|
| gptkbp:investmentFocus |
research and development
new technologies clinical development drug_discovery |
| gptkbp:market |
global
|
| gptkbp:partnerships |
non-profit organizations
biotechnology companies research institutions various academic institutions leading universities healthcare_organizations |
| gptkbp:patentCitation |
numerous drug formulations
|
| gptkbp:philanthropy |
mental health initiatives
community support programs |
| gptkbp:products |
antidepressants
antipsychotics |
| gptkbp:researchFocus |
gptkb:schizophrenia
Alzheimer's disease neurological disorders mood disorders |
| gptkbp:revenue |
approximately $2 billion
|
| gptkbp:specializesIn |
psychiatry
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
LUN
|
| gptkbp:sustainability |
social responsibility
environmental responsibility governance practices |
| gptkbp:website |
www.lundbeck.com
|